Paper Details

  1. Home
  2. Paper Details

The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.

Author: ColemanPaul J, FoxSteven V, GotterAnthony L, HodgsonRobert, RamirezAndres D, RengerJohn J, RoeckerAnthony J, SmithSean M, UslanerJason M, WinrowChristopher J, YaoLihang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effects of a dual orexin receptor antagonist (DORA) and a GABA<sub>A</sub> receptor modulator on neurochemical pathways associated with sleep architecture and cognitive performance. The DORA suppressed histamine release without affecting acetylcholine levels, while the GABA<sub>A</sub> modulator inhibited acetylcholine secretion and had variable effects on histamine release. The DORA's neurotransmitter profile suggests it may be a better option for insomnia treatment due to its selective wake reduction without cognitive impairment.
Paper Details　
Original Abstract of the Article :
Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non-restorative sleep. The therapeutic standard of care for this condition is treatment with gamma-aminobutyric acid (GABA)<sub>A</sub> receptor modulators, which promote sleep but are associated with a panop...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jnc.14055

データ提供：米国国立医学図書館（NLM）

DORA-22: A New Oasis for Restless Minds

[Chronic insomnia] is a common and debilitating condition that can leave individuals feeling lost and exhausted, like wandering through a vast, endless desert, unable to find rest. This research explores the potential of [DORA-22], a [dual orexin receptor antagonist], to offer a new oasis, a pathway to a more restful sleep.

The researchers, like explorers seeking a solution to this persistent problem, investigated the effects of DORA-22 on [neurotransmitter pathways] associated with sleep and wakefulness. They sought to understand how this novel drug interacts with the brain's delicate balance, hoping to find a more effective and well-tolerated approach to treating insomnia.

A New Oasis for Restless Minds: Targeting the Wake-Promoting Neurotransmitter

The study's findings suggest that DORA-22 can [suppress the release of histamine], a key neurotransmitter involved in promoting wakefulness. This is like finding a way to calm the desert winds that keep individuals awake at night, allowing for a more peaceful and restful sleep. This research offers a promising new approach to treating insomnia, targeting the root cause of wakefulness.

Finding Your Oasis: Seeking the Right Treatment for Insomnia

This research highlights the importance of finding the right treatment for insomnia, a condition that can have a profound impact on physical and mental health. It's about finding a way to navigate the desert of sleeplessness, finding an oasis that provides the rest and rejuvenation you need. Don't hesitate to consult with your healthcare provider to explore your options and find the best path toward a more restful sleep.

Dr.Camel's Conclusion

This study offers a beacon of hope for those who have been struggling with [chronic insomnia] for years. The development of [DORA-22] represents a significant step forward in the quest for effective insomnia treatment, offering a new oasis in the desert of sleepless nights. It's a reminder that with continued research and innovation, we can find more effective ways to manage even the most challenging medical conditions.

Date :
  1. Date Completed 2017-08-10
  2. Date Revised 2019-01-25
Further Info :

Pubmed ID

28444767

DOI: Digital Object Identifier

10.1111/jnc.14055

Related Literature

Article Analysis
・Side Effects of eszopiclone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.